Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 5Y returns in the bottom 25% of the category. | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 8/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 872 Cr | 8737 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹1000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.02% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 37 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.38%) Apollo Hospitals Enterprise Ltd (7.31%) Cipla Ltd (6.73%) Fortis Healthcare Ltd (5.19%) Abbott India Ltd (5.1%) | Sun Pharmaceuticals Industries Ltd (12.22%) Divi's Laboratories Ltd (7.55%) Lupin Ltd (5.93%) Cipla Ltd (5.69%) Dr Reddy's Laboratories Ltd (5.69%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (99.17%) Basic Materials (0.83%) | Health (100%) | ||
Equity % | 98.05% | 99.45% | ||
Debt % | - | - | ||
P/E | 40.34 | 37.97 | ||
P/B | 6.3 | 6.05 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.62% | -0.43% | ||
3-Month Return | 5.24% | 2.59% | ||
6-Month Return | 14.2% | 13.3% | ||
1-Year Return | -0.35% | 0.45% | ||
3-Year Return | 24.5% | 24.42% | ||
5-Year Return | 17.98% | 19.78% |
Sharpe | 1.01 | 1.06 | ||
Alpha | -0.17 | 0.66 | ||
Beta | 0.96 | 0.91 | ||
Standard Deviation | 15.94 | 15.05 | ||
Information Ratio | -0.26 | -0.24 |
Description | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dhaval Joshi,Dhaval Shah | Sailesh Raj Bhan,Kinjal Desai |